Literature DB >> 9452500

Latent alpha1-antichymotrypsin. A molecular explanation for the inactivation of alpha1-antichymotrypsin in chronic bronchitis and emphysema.

W S Chang1, D A Lomas.   

Abstract

alpha1-Antichymotrypsin is an acute phase protein that protects the tissues from damage by proteolytic enzymes, but previous studies have shown that alpha1-antichymotrypsin within the lungs of patients with chronic bronchitis and emphysema is intact but inactive as an inhibitor. Ammonium sulfate fractionation followed by blue Sepharose and DNA-Sepharose chromatography was used to isolate small amounts of intact, monomeric but inactive alpha1-antichymotrypsin from the plasma of 30 healthy blood donors. This species had a higher DNA binding affinity with more anodal electrophoretic mobility than native alpha1-antichymotrypsin and was conformationally stable against thermal denaturation, 8 M urea, and 7 M guanidinium chloride. The protein was unable to accept synthetic reactive loop peptides, and the reactive loop was resistant to proteolytic cleavage at the P5-P4 bond but could be cleaved between P1' and P3'. These data suggest that this new alpha1-antichymotrypsin species was in a conformation similar to those of the crystallographically determined latent serpins, plasminogen activator inhibitor-1 and antithrombin. alpha1-Antichymotrypsin from lung lavage migrated with the same electrophoretic mobility as the putative latent alpha1-antichymotrypsin, suggesting that this is the inactive conformation described previously in the lungs of patients with chronic bronchitis and emphysema. This conformational transition of alpha1-antichymotrypsin, from an active to an inactive state, within the lung may play an important role in the pathogenesis of chronic lung disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9452500     DOI: 10.1074/jbc.273.6.3695

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease.

Authors:  B Gooptu; B Hazes; W S Chang; T R Dafforn; R W Carrell; R J Read; D A Lomas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease.

Authors:  P R Elliott; X Y Pei; T R Dafforn; D A Lomas
Journal:  Protein Sci       Date:  2000-07       Impact factor: 6.725

3.  Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.

Authors:  P Krüger; S Verheyden; P J Declerck; Y Engelborghs
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

Review 4.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

5.  The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.

Authors:  Yu-Ran Na; Hana Im
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

6.  Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1.

Authors:  Stefan Verheyden; Alain Sillen; Ann Gils; Paul J Declerck; Yves Engelborghs
Journal:  Biophys J       Date:  2003-07       Impact factor: 4.033

7.  Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.

Authors:  Marie-Louise Zani; Kévin Baranger; Nicolas Guyot; Sandrine Dallet-Choisy; Thierry Moreau
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

8.  Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibody.

Authors:  Lu Tan; Juan Perez; Marianna Mela; Elena Miranda; Keith A Burling; Farshid N Rouhani; Dawn L DeMeo; Imran Haq; James A Irving; Adriana Ordóñez; Jennifer A Dickens; Mark Brantly; Stefan J Marciniak; Graeme J M Alexander; Bibek Gooptu; David A Lomas
Journal:  Int J Biochem Cell Biol       Date:  2014-11-13       Impact factor: 5.085

Review 9.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.